Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 297.99 Billion KRW | 311.19% |
| 2022 | 256.53 Billion KRW | 16.65% |
| 2021 | 219.91 Billion KRW | 4.04% |
| 2020 | 211.37 Billion KRW | -0.36% |
| 2019 | 212.12 Billion KRW | 14.58% |
| 2018 | 185.13 Billion KRW | -3.77% |
| 2017 | 192.39 Billion KRW | -7.2% |
| 2016 | 207.31 Billion KRW | 13.25% |
| 2015 | 183.05 Billion KRW | 7.23% |
| 2014 | 170.71 Billion KRW | 13.5% |
| 2013 | 150.4 Billion KRW | -61.67% |
| 2012 | 392.34 Billion KRW | -3.83% |
| 2011 | 407.96 Billion KRW | 2.23% |
| 2010 | 399.06 Billion KRW | 6.05% |
| 2009 | 376.29 Billion KRW | 7.0% |
| 2008 | 351.65 Billion KRW | 15.6% |
| 2007 | 304.19 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 56.27 Billion KRW | 17.92% |
| 2024 Q1 | 72.79 Billion KRW | -74.58% |
| 2023 Q2 | -77.32 Billion KRW | -221.92% |
| 2023 Q1 | 63.42 Billion KRW | -1.68% |
| 2023 Q4 | 286.33 Billion KRW | 208.28% |
| 2023 FY | 1054.83 Billion KRW | 311.19% |
| 2023 Q3 | -264.45 Billion KRW | -241.98% |
| 2022 Q1 | 63.29 Billion KRW | 17.04% |
| 2022 Q2 | 67.79 Billion KRW | 7.11% |
| 2022 Q3 | 60.93 Billion KRW | -10.12% |
| 2022 Q4 | 64.51 Billion KRW | 5.87% |
| 2022 FY | 256.53 Billion KRW | 16.65% |
| 2021 Q1 | 51.52 Billion KRW | 1.64% |
| 2021 Q2 | 57.15 Billion KRW | 10.94% |
| 2021 Q3 | 57.16 Billion KRW | 0.01% |
| 2021 Q4 | 54.07 Billion KRW | -5.39% |
| 2021 FY | 219.91 Billion KRW | 4.04% |
| 2020 Q2 | 54.52 Billion KRW | 14.41% |
| 2020 FY | 211.37 Billion KRW | -0.36% |
| 2020 Q1 | 47.65 Billion KRW | -7.9% |
| 2020 Q4 | 50.68 Billion KRW | -13.35% |
| 2020 Q3 | 58.5 Billion KRW | 7.29% |
| 2019 Q1 | 45.6 Billion KRW | -0.15% |
| 2019 FY | 212.12 Billion KRW | 14.58% |
| 2019 Q4 | 51.74 Billion KRW | -6.07% |
| 2019 Q3 | 55.08 Billion KRW | -7.7% |
| 2019 Q2 | 59.68 Billion KRW | 30.88% |
| 2018 Q2 | 46.06 Billion KRW | 0.68% |
| 2018 Q1 | 45.75 Billion KRW | -4.84% |
| 2018 FY | 185.13 Billion KRW | -3.77% |
| 2018 Q4 | 45.67 Billion KRW | -4.14% |
| 2018 Q3 | 47.64 Billion KRW | 3.44% |
| 2017 FY | 192.39 Billion KRW | -7.2% |
| 2017 Q4 | 48.07 Billion KRW | -4.36% |
| 2017 Q3 | 50.27 Billion KRW | 5.62% |
| 2017 Q2 | 47.59 Billion KRW | 2.47% |
| 2017 Q1 | 46.44 Billion KRW | -29.96% |
| 2016 Q2 | 51.51 Billion KRW | 18.4% |
| 2016 FY | 207.31 Billion KRW | 13.25% |
| 2016 Q4 | 66.31 Billion KRW | 44.25% |
| 2016 Q1 | 43.51 Billion KRW | -7.38% |
| 2016 Q3 | 45.97 Billion KRW | -10.77% |
| 2015 Q2 | 47.44 Billion KRW | 13.39% |
| 2015 FY | 183.05 Billion KRW | 7.23% |
| 2015 Q1 | 41.84 Billion KRW | 0.8% |
| 2015 Q4 | 46.97 Billion KRW | 0.39% |
| 2015 Q3 | 46.79 Billion KRW | -1.37% |
| 2014 FY | 170.71 Billion KRW | 13.5% |
| 2014 Q3 | 45.5 Billion KRW | -1.53% |
| 2014 Q2 | 46.21 Billion KRW | 23.3% |
| 2014 Q4 | 41.5 Billion KRW | -8.78% |
| 2014 Q1 | 37.48 Billion KRW | 13.66% |
| 2013 Q4 | 32.97 Billion KRW | -10.63% |
| 2013 FY | 150.4 Billion KRW | -61.67% |
| 2013 Q1 | 37.06 Billion KRW | -86.88% |
| 2013 Q2 | 43.46 Billion KRW | 17.25% |
| 2013 Q3 | 36.9 Billion KRW | -15.09% |
| 2012 FY | 392.34 Billion KRW | -3.83% |
| 2012 Q1 | 95.73 Billion KRW | 0.0% |
| 2012 Q2 | 39.96 Billion KRW | -58.25% |
| 2012 Q3 | 36.21 Billion KRW | -9.38% |
| 2012 Q4 | 282.53 Billion KRW | 680.08% |
| 2011 FY | 407.96 Billion KRW | 2.23% |
| 2011 Q3 | 100.01 Billion KRW | -2.58% |
| 2011 Q1 | 97.85 Billion KRW | 0.0% |
| 2011 Q2 | 102.67 Billion KRW | 4.92% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 94.74 Billion KRW | -10.9% |
| 2010 FY | 399.06 Billion KRW | 6.05% |
| 2010 Q2 | 106.32 Billion KRW | 10.74% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 96.01 Billion KRW | 0.0% |
| 2009 Q3 | 96.21 Billion KRW | -3.39% |
| 2009 Q2 | 99.58 Billion KRW | 4.9% |
| 2009 Q1 | 94.93 Billion KRW | 0.0% |
| 2009 FY | 376.29 Billion KRW | 7.0% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 FY | 351.65 Billion KRW | 15.6% |
| 2008 Q3 | 91.56 Billion KRW | 0.94% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q1 | 86.81 Billion KRW | 0.0% |
| 2008 Q2 | 90.71 Billion KRW | 4.49% |
| 2007 Q1 | 79.31 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 304.19 Billion KRW | 0.0% |
| 2007 Q2 | 75.72 Billion KRW | -4.52% |
| 2007 Q3 | 78.67 Billion KRW | 3.89% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -530.617% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -7.022% |
| HANDOK Inc. | 153.76 Billion KRW | -93.792% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -330.539% |
| Yuhan Corporation | 489.94 Billion KRW | 39.179% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 2.921% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -613.077% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 51.227% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -313.973% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -71.113% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -643.99% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -218.532% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -159.744% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -530.617% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -601.622% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -297.061% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -408.134% |
| JW Holdings Corporation | 301.25 Billion KRW | 1.084% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -14.192% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 27.08% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -24.729% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -133.408% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -336.228% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -353.209% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -70.353% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -530.617% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -19.616% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 46.828% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -24.729% |
| Yuhan Corporation | 489.94 Billion KRW | 39.179% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -53.871% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -328.959% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -431.823% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -24.729% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -135.766% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -152.078% |
| CKD Bio Corp. | 25.19 Billion KRW | -1082.705% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -34.231% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -80.477% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -348.665% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -133.408% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 15.033% |
| Boryung Corporation | 285.16 Billion KRW | -4.499% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -240.398% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -71.113% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1370.722% |